[ad_1]
Emmanuelle Charpentier, Jennifer Doudna and Feng Zhang are three of the pioneers of CRISPR-Cas9 use. Doudna and Zhang helped launch Editas Medicine in 2013, but Doudna left the following year to join Intellia Therapeutics.
Intellia Therapeutics currently has a valuation of more than $ 700 million. Editas is worth more than $ 1.3 billion. As CRISPR's chief scientist and co-discoverer, Jennifer Doudna clearly holds a significant share of Editas and Intellia shares.
Unsurprisingly, Doudna issued a statement condemning the controversy brought to the genetic modification of human embryos.
It is essential that this news does not detract from the many important clinical efforts to use CRISPR technology to treat and cure diseases in adults and children. Public and transparent discussion of the many uses of genome modification technology should continue, as will be the case at the Human Genome Publishing Summit in Hong Kong over the next three days.
The modification of the human gene of embryos is very controversial. A major shareholder in CRISPR companies hates any controversial use of CRISPR that may trigger a brutal reaction against CRISPR activities.
Source link
